News
Investors
Overview
Events & Presentations
Stock Information
- Stock Quote & Chart
- Historic Stock Lookup
- Analyst Coverage
Press Releases
Corporate Governance
- Committee Composition
- IRS – Required Disclosures
State Compliance
SEC Filings
Email Alerts
FAQs
Careers
Contacts
About Us
Our Mission & Vision
The Zevra Story
Leadership
Board of Directors
What We Do
Partnering
Patients & Caregivers
Clinical Trials
Expanded Access Policy
Niemann-Pick Disease Type C
Urea Cycle Disorders
Vascular Ehlers-Danlos
Sleep Disorders
Our Products
MIPLYFFA®
OLPRUVA®
AZSTARYS®
Our Pipeline
Pipeline
Clinical Trials
Publications & Presentations
Medical Literature
Medical Information
Investigator-Initiated Studies
News
Investors
Overview
Events & Presentations
Stock Information
- Stock Quote & Chart
- Historic Stock Lookup
- Analyst Coverage
Press Releases
Corporate Governance
- Committee Composition
- IRS – Required Disclosures
State Compliance
SEC Filings
Email Alerts
FAQs
Careers
Contacts
Home
>
Latest
>
Evaluation of the Long-Term Effect of Arimoclomol in NPC – 48 Months Data from CT-ORZY-NPC-002
Evaluation of the Long-Term Effect of Arimoclomol in NPC – 48 Months Data from CT-ORZY-NPC-002
News
Careers
Contacts
